IBP-9414 is under clinical development by Infant Bacterial Therapeutics and currently in Phase III for Necrotizing Enterocolitis. According to GlobalData, Phase III drugs for Necrotizing Enterocolitis does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IBP-9414 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IBP-9414 overview
IBP-9414 is under development for the prevention of necrotising enterocolitis (NCE) in premature infants. The drug candidate is administered through oral route. It constitutes co-evolved human bacterial single strain Lactobacillus reuteri derived from human breast milk.
Infant Bacterial Therapeutics overview
Infant Bacterial Therapeutics (IBT) is a pharmaceutical company. It specializes in the development and marketing of drugs aimed at diseases affecting prematurely born infants or those caused by antibiotic-resistant bacteria. The company primarily focuses on its drug candidate, IBP-9414, that is designed to reduce the incidence of necrotizing enterocolitis (NEC) and improve sustained feeding tolerance (SFT) in prematurely born infants. IBT’s portfolio includes drug candidates IBP-1016, IBP-1118, and IBP-1122, that target gastroschisis, retinopathy of prematurity (ROP), and vancomycin-resistant enterococci (VRE) respectively. The company’s products are primarily used in the healthcare industry, specifically in neonatal care. The company operates in the US, Sweden and Europe. IBT is headquartered in Stockholm, Sweden.
For a complete picture of IBP-9414’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
